Loading...
XSHG
600332
Market cap4.81bUSD
Jul 10, Last price  
21.29CNY
1D
0.33%
1Q
-7.11%
Jan 2017
-11.22%
Name

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Chart & Performance

D1W1MN
XSHG:600332 chart
P/E
17.73
P/S
0.68
EPS
1.20
Div Yield, %
3.53%
Shrs. gr., 5y
Rev. gr., 5y
4.72%
Revenues
77.66b
+3.55%
10,241,003,50512,320,776,8803,527,423,9183,881,938,4674,486,067,3285,439,611,6188,229,058,53817,608,193,31218,799,880,60419,124,658,29820,035,681,49920,954,225,18942,233,838,05164,951,777,64161,673,702,45069,014,052,34770,788,155,06875,515,403,99474,992,820,47377,656,109,939
Net income
2.98b
+5.21%
227,327,746335,147,247182,496,241210,988,923267,111,879287,530,980395,278,360980,045,0771,192,471,6361,300,351,2921,508,032,6712,061,651,9293,440,980,1033,188,884,6382,915,244,5763,719,877,6803,966,522,2184,055,678,6912,835,496,1632,983,113,594
CFO
253m
-92.64%
38,880,433375,741,6616,103,479439,393,13573,168,7700506,529,7321,339,140,1381,761,382,1831,941,956,4972,444,671,6281,833,690,7255,216,888,4855,022,366,882585,185,0235,673,496,7546,999,076,1824,103,624,9973,442,427,000253,499,268
Dividend
Jun 18, 20240.749 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL), along with its various subsidiaries, operates as a comprehensive pharmaceutical enterprise. It is actively engaged in the research, development, production, and distribution of a wide array of products, including traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials, natural and biological medications, and chemical raw material intermediates. Its operations span both the People's Republic of China and international markets. The company structures its extensive operations into four primary segments: Great Southern TCM, Great Commerce, Great Health, and a miscellaneous 'Others' category. Beyond its core pharmaceutical manufacturing, GBPHCL's activities extend to the wholesale, retail, import, and export of both Western and traditional Chinese medicines, as well as medical apparatus and instruments. Furthermore, its diverse product portfolio encompasses the research, development, production, and sale of consumer health items such as beverages, various food products (including pre-packaged items and dairy), and a broad range of pharmaceutical formulations like tablets, capsules, lozenges, injections, and even traditional specialties like tortoise herb jelly. The group also strategically invests in the broader health industry, focusing on areas like medical care, health management, health preservation, and elderly care. Complementing these activities, it offers commercial and advertising services. As of December 31, 2021, GBPHCL maintained a substantial retail presence, operating 154 chain pharmacy outlets. This network comprised 22 Cai Zhi Lin pharmacies, 36 Jian Min pharmacies, 51 GPC Prescription Pharmacy locations, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd. outlets, alongside an additional 22 general retail stores. Tracing its origins back to its incorporation in 1997, the company was initially known as Guangzhou Pharmaceutical Company Limited. It adopted its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. The company is headquartered in Guangzhou, China.
IPO date
Oct 21, 1997
Employees
23,493
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT